MedTrace Logo

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

NCT01232881 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2011-04-28

No results posted yet for this study

Summary

This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.

Conditions

Interventions

PROCEDURE

Tumor Sample

Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.

PROCEDURE

Serum Sample

Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Indiana University School of Medicine

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • Hoosier Cancer Research Network

    lead OTHER

Principal Investigators

  • George Sledge, M.D. · Hoosier Cancer Research Network

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01232881 on ClinicalTrials.gov